vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $340.0M, roughly 1.8× Walker & Dunlop, Inc.). Walker & Dunlop, Inc. runs the higher net margin — -12.9% vs -14.8%, a 1.9% gap on every dollar of revenue. On growth, Walker & Dunlop, Inc. posted the faster year-over-year revenue change (-0.4% vs -10.5%). Over the past eight quarters, Walker & Dunlop, Inc.'s revenue compounded faster (22.1% CAGR vs -6.6%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
QDEL vs WD — Head-to-Head
Income Statement — Q1 FY2027 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $619.8M | $340.0M |
| Net Profit | $-91.8M | $-13.9M |
| Gross Margin | — | — |
| Operating Margin | — | -17.2% |
| Net Margin | -14.8% | -12.9% |
| Revenue YoY | -10.5% | -0.4% |
| Net Profit YoY | — | -131.0% |
| EPS (diluted) | $-1.35 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $619.8M | — | ||
| Q4 25 | — | $340.0M | ||
| Q3 25 | $699.9M | $337.7M | ||
| Q2 25 | $613.9M | $319.2M | ||
| Q1 25 | $692.8M | $237.4M | ||
| Q4 24 | $707.8M | $341.5M | ||
| Q3 24 | $727.1M | $292.3M | ||
| Q2 24 | $637.0M | $270.7M |
| Q1 26 | $-91.8M | — | ||
| Q4 25 | — | $-13.9M | ||
| Q3 25 | $-733.0M | $33.5M | ||
| Q2 25 | $-255.4M | $34.0M | ||
| Q1 25 | $-12.7M | $2.8M | ||
| Q4 24 | $-178.4M | $44.8M | ||
| Q3 24 | $-19.9M | $28.8M | ||
| Q2 24 | $-147.7M | $22.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | -17.2% | ||
| Q3 25 | -100.7% | 13.6% | ||
| Q2 25 | -29.4% | 14.5% | ||
| Q1 25 | 4.7% | 2.2% | ||
| Q4 24 | -14.2% | 15.3% | ||
| Q3 24 | 2.1% | 12.8% | ||
| Q2 24 | -18.4% | 10.4% |
| Q1 26 | -14.8% | — | ||
| Q4 25 | — | -12.9% | ||
| Q3 25 | -104.7% | 9.9% | ||
| Q2 25 | -41.6% | 10.6% | ||
| Q1 25 | -1.8% | 1.2% | ||
| Q4 24 | -25.2% | 13.1% | ||
| Q3 24 | -2.7% | 9.9% | ||
| Q2 24 | -23.2% | 8.4% |
| Q1 26 | $-1.35 | — | ||
| Q4 25 | — | $-0.41 | ||
| Q3 25 | $-10.78 | $0.98 | ||
| Q2 25 | $-3.77 | $0.99 | ||
| Q1 25 | $-0.19 | $0.08 | ||
| Q4 24 | $-2.54 | $1.32 | ||
| Q3 24 | $-0.30 | $0.85 | ||
| Q2 24 | $-2.20 | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $140.4M | $299.3M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $1.9B | $1.7B |
| Total Assets | $5.6B | $5.1B |
| Debt / EquityLower = less leverage | 1.33× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $140.4M | — | ||
| Q4 25 | — | $299.3M | ||
| Q3 25 | $98.1M | $274.8M | ||
| Q2 25 | $151.7M | $233.7M | ||
| Q1 25 | $127.1M | $181.0M | ||
| Q4 24 | $98.3M | $279.3M | ||
| Q3 24 | $143.7M | $179.8M | ||
| Q2 24 | $107.0M | $208.1M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
| Q1 26 | $1.9B | — | ||
| Q4 25 | — | $1.7B | ||
| Q3 25 | $2.0B | $1.8B | ||
| Q2 25 | $2.8B | $1.8B | ||
| Q1 25 | $3.0B | $1.7B | ||
| Q4 24 | $3.0B | $1.7B | ||
| Q3 24 | $3.2B | $1.7B | ||
| Q2 24 | $3.2B | $1.7B |
| Q1 26 | $5.6B | — | ||
| Q4 25 | — | $5.1B | ||
| Q3 25 | $5.7B | $5.8B | ||
| Q2 25 | $6.4B | $4.7B | ||
| Q1 25 | $6.5B | $4.5B | ||
| Q4 24 | $6.4B | $4.4B | ||
| Q3 24 | $6.8B | $4.6B | ||
| Q2 24 | $6.7B | $4.2B |
| Q1 26 | 1.33× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-664.3M |
| Free Cash FlowOCF − Capex | — | $-680.1M |
| FCF MarginFCF / Revenue | — | -200.0% |
| Capex IntensityCapex / Revenue | — | 4.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-664.3M | ||
| Q3 25 | $-45.5M | $-948.1M | ||
| Q2 25 | $-46.8M | $-238.5M | ||
| Q1 25 | $65.6M | $-281.1M | ||
| Q4 24 | $63.7M | $129.4M | ||
| Q3 24 | $117.9M | $-202.0M | ||
| Q2 24 | $-97.9M | $-237.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-680.1M | ||
| Q3 25 | $-94.7M | $-950.4M | ||
| Q2 25 | $-84.3M | $-241.0M | ||
| Q1 25 | $9.4M | $-284.7M | ||
| Q4 24 | $16.5M | $116.4M | ||
| Q3 24 | $71.4M | $-204.0M | ||
| Q2 24 | $-133.2M | $-241.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | -200.0% | ||
| Q3 25 | -13.5% | -281.5% | ||
| Q2 25 | -13.7% | -75.5% | ||
| Q1 25 | 1.4% | -120.0% | ||
| Q4 24 | 2.3% | 34.1% | ||
| Q3 24 | 9.8% | -69.8% | ||
| Q2 24 | -20.9% | -89.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.6% | ||
| Q3 25 | 7.0% | 0.7% | ||
| Q2 25 | 6.1% | 0.8% | ||
| Q1 25 | 8.1% | 1.5% | ||
| Q4 24 | 6.7% | 3.8% | ||
| Q3 24 | 6.4% | 0.7% | ||
| Q2 24 | 5.5% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -28.34× | ||
| Q2 25 | — | -7.02× | ||
| Q1 25 | — | -102.07× | ||
| Q4 24 | — | 2.89× | ||
| Q3 24 | — | -7.01× | ||
| Q2 24 | — | -10.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
WD
Segment breakdown not available.
